Geode Capital Management LLC Has $650,000 Position in CEL-SCI Co. (NYSE:CVM)

Geode Capital Management LLC boosted its holdings in shares of CEL-SCI Co. (NYSE:CVM) by 9.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 612,861 shares of the company’s stock after buying an additional 53,879 shares during the period. Geode Capital Management LLC’s holdings in CEL-SCI were worth $650,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Calton & Associates Inc. acquired a new stake in CEL-SCI during the third quarter worth $50,000. Black Diamond Financial LLC boosted its stake in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after buying an additional 19,000 shares in the last quarter. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI during the third quarter worth $98,000. Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after buying an additional 40,000 shares in the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Stock Up 16.0 %

Shares of NYSE:CVM opened at $0.43 on Friday. CEL-SCI Co. has a 52 week low of $0.36 and a 52 week high of $3.08. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. The company’s fifty day moving average is $0.61 and its 200-day moving average is $0.94. The company has a market capitalization of $31.46 million, a PE ratio of -0.73 and a beta of 0.65.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of CEL-SCI in a research note on Wednesday. They issued a “sell” rating on the stock.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.